Keytruda (pembrolizumab) Letter of Medical Necessity
Keytruda (pembrolizumab) prior authorization is highly indication-specific. The LMN must specify the exact tumor type, line of therapy, and biomarker results supporting eligibility.
FDA-Approved Indications
- ● multiple solid tumors including melanoma, NSCLC, head and neck, urothelial, renal, endometrial, MSI-H tumors and many others
Why Keytruda Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Biomarker testing not documented (PD-L1, MSI, TMB)
- 2. Line of therapy not specified
- 3. Combination regimen not justified
What to Include in a Keytruda Letter of Medical Necessity
Document tumor type with histology, stage, line of therapy, biomarker testing (PD-L1 CPS/TPS, MSI, TMB, MMR), prior treatments, and the specific NCCN-supported regimen being requested.
Key clinical evidence to cite:
- ✓ KEYNOTE-001 through KEYNOTE-826 series across tumor types
Relevant guidelines:
- 📖 NCCN guidelines for each tumor type
- 📖 ASCO guidelines
Keytruda Prior Authorization Criteria
Standard criteria across major US payers for Keytruda. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Keytruda
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Keytruda Prior Authorization FAQ
Why was my Keytruda prior authorization denied?
The most common denial reasons for Keytruda are: Biomarker testing not documented (PD-L1, MSI, TMB); Line of therapy not specified; Combination regimen not justified.
What should a Keytruda Letter of Medical Necessity include?
Document tumor type with histology, stage, line of therapy, biomarker testing (PD-L1 CPS/TPS, MSI, TMB, MMR), prior treatments, and the specific NCCN-supported regimen being requested.
Which payers cover Keytruda?
Keytruda is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.